| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10965127 | Vaccine | 2015 | 11 Pages |
Abstract
AERAS-402 has an acceptable safety profile in infants and was well tolerated at all dose levels. Response rate was lower than previously seen in BCG vaccinated adults, and frequency and magnitude of antigen-specific T cells were not increased by a third dose of vaccine.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
M. Tameris, D.A. Hokey, V. Nduba, J. Sacarlal, F. Laher, G. Kiringa, K. Gondo, E.M. Lazarus, G.E. Gray, S. Nachman, H. Mahomed, K. Downing, B. Abel, T.J. Scriba, J.B. McClain, M.G. Pau, J. Hendriks, V. Dheenadhayalan, M. Hatherill,